Posting of Report and Accounts and Notice of AGM

RNS Number : 8480D

WideCells Group PLC

02 May 2017

 

2 May 2017

WideCells Group PLC ('WideCells Group' or 'the Company')

Annual Report and Accounts for the year ended 31 December 2016 and Notice of Annual General Meeting

WideCells Group PLC ('WideCells' or the 'Company'), the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, announces that its Annual Report and Accounts for the year ended 31 December 2016 and a Notice of Annual General Meeting ("AGM") have been posted to shareholders and are available to download on the Company's website at http://www.widecellsgroup.com/.

The AGM will be held on 22 June 2017 at the Core Technology Facility, 46 Grafton Street, Manchester, M13 9NT at 12.00 noon.

**ENDS**

For further information, please visit the Company's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

WideCells Group	CEO - João Andrade	Tel:  [phone]
Smaller Company Capital Ltd	Broker - Jeremy Woodgate & Rupert Williams	Tel: [phone]
Shard Capital Partners LLP	Broker - Damon Heath & Erik Woolgar	Tel: [phone]
St Brides Partners Ltd	PR - Elisabeth Cowell & Charlotte Page	Tel: [phone]

Notes to Editors

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. The Directors believe that the use of cord blood stem cells for transplant will drive one of the next important phases in medicine and is therefore developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry.  With this in mind, it has created three divisions:

·     CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.

·     WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising on stem cell storage.

·     WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

Stem Cell Fast Facts:

·     Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow - WideCells is focused on promoting the collection and storage of this.

·     Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.

·     82 illnesses can currently be treated using stem cell procedures.

·     Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014.

 

END

 

 

MSCFMGGKVZFGNZG